GYRE: Gyre Therapeutics, Inc.
About
Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis). The firm operates through the BC and Gyre segments. The company was founded on March 7, 1997 and is headquartered in San Diego, CA.
Current Value
$12.001 Year Return
Current Value
$12.001 Year Return
Key Details
Market Cap
$1.10B
P/E Ratio
-0.67
1Y Stock Return
-27.06%
1Y Revenue Growth
-100.00%
Dividend Yield
0.00%
Price to Book
16.0
Strategies that include GYRE
Stock's related to GYRE
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| ALDX | -<0.01% | $286.43M | +90.12% | 0.00% |
| GVA | -0.01% | $4.29B | +115.14% | 0.53% |
| TGNA | 0.01% | $2.98B | +16.99% | 2.54% |
| KMB | 0.02% | $45.70B | +12.03% | 3.52% |
| MKL | 0.02% | $22.10B | +20.21% | 0.00% |
| CPT | -0.03% | $13.01B | +37.97% | 3.34% |
| GBX | 0.03% | $2.07B | +75.87% | 1.81% |
| RES | 0.04% | $1.32B | -15.98% | 2.58% |
| GIFI | -0.04% | $116.11M | +72.33% | 0.00% |
| TEF | 0.05% | $24.97B | +7.52% | 7.35% |
| AIV | -0.05% | $1.24B | +30.07% | 0.00% |
| STZ | 0.06% | $43.71B | +0.72% | 1.63% |
| KVUE | 0.06% | $46.19B | +20.21% | 3.36% |
| PARAA | -0.06% | $15.54B | +30.31% | 0.87% |
| CTRA | -0.07% | $20.21B | +2.89% | 3.06% |
| LGF.B | 0.07% | $1.73B | -17.95% | 0.00% |
| NJR | 0.07% | $4.94B | +16.77% | 3.41% |
| NXTC | -0.08% | $36.13M | +3.20% | 0.00% |
| EXE | 0.09% | $23.33B | +23.61% | 2.30% |
| IONS | -0.09% | $5.36B | -31.55% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| QDEL | -19.97% | $2.55B | -45.10% | 0.00% |
| EYPT | -19.33% | $446.88M | +39.17% | 0.00% |
| QXO | -18.47% | $6.81B | -33.42% | 0.00% |
| HRL | -17.66% | $16.73B | -6.41% | 3.69% |
| CAE | -15.08% | $7.43B | +11.42% | 0.00% |
| CORZ | -14.78% | $4.90B | +3,634.04% | 0.00% |
| FDP | -13.56% | $1.61B | +44.02% | 2.97% |
| PGR | -13.50% | $154.33B | +62.01% | 0.44% |
| ACGL | -13.18% | $37.09B | +20.63% | 0.00% |
| MSDL | -12.49% | $1.83B | +0.95% | 7.27% |
| CPB | -12.12% | $13.23B | +8.54% | 3.29% |
| GIS | -11.87% | $35.60B | -1.16% | 3.70% |
| CAG | -10.89% | $12.97B | -4.09% | 5.14% |
| HLN | -10.65% | $43.23B | +14.51% | 1.63% |
| CIG | -10.11% | $3.79B | +18.19% | 0.00% |
| GL | -10.08% | $9.15B | -9.45% | 0.86% |
| NOC | -9.97% | $72.32B | +5.29% | 1.58% |
| INSG | -9.35% | $182.60M | +533.30% | 0.00% |
| EDR | -9.32% | $9.11B | +20.37% | 0.81% |
| AON | -9.19% | $82.75B | +16.30% | 0.69% |
ETF's related to GYRE
News
Yahoo
Gyre Therapeutics ( NASDAQ:GYRE ) Third Quarter 2024 Results Key Financial Results Revenue: US$25.5m (down 17% from 3Q...
Yahoo
Last patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in Q1 2025 On track to initiate U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis in 2025 Commercial launch of avatrombopag maleate tablets expected by the first half of 2025 Commercial launch of nintedanib expected in 2025 Cash and cash equivalents totaled $15.9 million as of September 30, 2024 SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYR
Finnhub
Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update Last patient completed pivotal Phase 3 trial in CHB-associated liver...
Yahoo
SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced that the last patient in Gyre Pharmaceuticals’ pivotal Phase 3 trial in the People’s Republic of China (“PRC”) evaluating F351 (hydronidone) for Chronic Hepatitis B (“CHB”)-associated liver fibrosis has completed the 52-week study. Gyre Pharmaceut
Yahoo
Key Insights Significant control over Gyre Therapeutics by public companies implies that the general public has more...
Yahoo
SAN DIEGO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced that Han Ying, PhD, Chief Executive Officer, will be presenting a company overview at the 8th Annual H.C. Wainwright MASH Investor Conference on Monday, October 7, 2024, at 2:30 PM ET (11:30 AM PT). The live webcast will be available on the Events and P
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.